Sei Investments Co. cut its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 38.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,386 shares of the biotechnology company’s stock after selling 4,520 shares during the quarter. Sei Investments Co.’s holdings in Mirati Therapeutics were worth $1,193,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. BlackRock Inc. increased its stake in Mirati Therapeutics by 6.8% during the first quarter. BlackRock Inc. now owns 4,573,591 shares of the biotechnology company’s stock worth $783,456,000 after acquiring an additional 293,179 shares during the last quarter. Boxer Capital LLC grew its stake in shares of Mirati Therapeutics by 13.3% in the first quarter. Boxer Capital LLC now owns 2,000,000 shares of the biotechnology company’s stock valued at $342,600,000 after buying an additional 234,440 shares in the last quarter. RTW Investments LP grew its stake in shares of Mirati Therapeutics by 26.4% in the first quarter. RTW Investments LP now owns 1,333,232 shares of the biotechnology company’s stock valued at $228,383,000 after buying an additional 278,868 shares in the last quarter. Orbimed Advisors LLC grew its stake in shares of Mirati Therapeutics by 6.6% in the first quarter. Orbimed Advisors LLC now owns 1,221,200 shares of the biotechnology company’s stock valued at $209,192,000 after buying an additional 75,900 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Mirati Therapeutics by 0.3% in the first quarter. Janus Henderson Group PLC now owns 1,156,163 shares of the biotechnology company’s stock valued at $198,049,000 after buying an additional 3,594 shares in the last quarter.
NASDAQ:MRTX opened at $177.45 on Tuesday. The business’s 50 day moving average is $158.70 and its two-hundred day moving average is $163.06. Mirati Therapeutics, Inc. has a 52 week low of $131.46 and a 52 week high of $249.42. The company has a market cap of $9.16 billion, a PE ratio of -17.85 and a beta of 1.37.
A number of equities research analysts have recently issued reports on MRTX shares. Zacks Investment Research upgraded Mirati Therapeutics from a “sell” rating to a “hold” rating and set a $172.00 target price for the company in a research note on Friday, July 9th. JPMorgan Chase & Co. lowered their target price on Mirati Therapeutics from $205.00 to $203.00 and set an “overweight” rating for the company in a research note on Tuesday, September 7th. SVB Leerink reiterated a “buy” rating on shares of Mirati Therapeutics in a research note on Sunday. Jefferies Financial Group began coverage on Mirati Therapeutics in a research note on Monday. They issued a “buy” rating and a $193.00 target price for the company. Finally, Morgan Stanley began coverage on Mirati Therapeutics in a report on Thursday, August 26th. They issued an “equal weight” rating and a $160.00 price target for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $211.87.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm’s products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics, Inc. (NASDAQ:MRTX).
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.